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1. Introduction 
Attempts to prevent criminal conduct have typically involved social or environmental 
manipulations, with incarceration, probation regimens, and psychological rehabilitation 
programmes being perhaps the most prominent examples. However, biological 
interventions have also at times been used for this purpose, and one of the 
presuppositions of this volume is that a wider range of biological interventions capable of 
preventing crime may be available in the future. 
 
This chapter sets the scene for the subsequent philosophical discussions by surveying a 
number of biological interventions that have been used, or might in the future be used, for 
the purposes of crime prevention. These interventions are pharmaceutical interventions 
intended to suppress libido, treat substance abuse or attention deficit-hyperactivity 
disorder (ADHD), or modulate serotonin activity; nutritional interventions; and electrical 
and magnetic brain stimulation. Where applicable, we briefly comment on the historical 
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use of these interventions, and in each case we discuss the evidence that they are 
effective, or might become so with further refinement. 
 
The list of interventions that we review is not exhaustive. For example, we have nothing 
to say about the frontal leucotomy and other forms of psychosurgery that were used for 
crime prevention (among other purposes) in the Twentieth Century. We will also not 
comment on the lethal injection, though it is a biological intervention that has arguably 
been used at least in part with the purpose of preventing crime. Our aim is to survey the 
kinds of biological intervention that are most likely to be justifiably and widely deployed 
as part of attempts to prevent crime in the future. As such, we focus on interventions that 
are relatively safe and/or non-invasive and for which there is some evidence of 
effectiveness or potential future effectiveness.  
 
We do not limit ourselves to particular types of crime, but as it happens, the interventions 
we survey are most likely to be effective in combating certain forms of either sexual 
crime, or non-sexual violent crime. It should be noted that the psychological, sociological 
and biological mechanisms underlying these two types of crime are thought to be 
different;1 our inclusion of interventions relevant to both types of crime should not be 
                                                 
1 David Thornton, Ruth Mann, Steve Webster, Linda Blud, Rosie Travers, Caroline Friendship, 
and Matt Erikson, ‘Distinguishing and Combining Risks for Sexual and Violent Recidivism’, 
Annals of the New York Academy of Sciences 989 (2003), pp. 225–35; R. Karl Hanson, Heather 
Scott, and Richard A. Steffy, ‘A Comparison of Child Molesters and Nonsexual Criminals: Risk 
Predictors and Long-Term Recidivism’, Journal of Research in Crime and Delinquency 32 
(1995), pp. 325–37; Anton van Wijk, Robert Vermeiren, Rolf Loeber, Lisette’t Hart-Kerkhoffs, 
Theo Doreleijers, Ruud Bullens, ‘Juvenile Sex Offenders Compared to Non-Sex Offenders’, 
Trauma, Violence, & Abuse 7 (2006), pp. 227–43; Leam A. Craig, Kevin D. Browne, Anthony 
Beech, and Ian Stringer, ‘Differences in Personality and Risk Characteristics in Sex, Violent and 
General Offenders’, Criminal Behaviour and Mental Health 16 (2006), pp. 183–94. 
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taken to suggest otherwise, nor do we mean to suggest that these broad categories of 
crime are homogenous with respect to the underlying causal mechanisms.  
 
2. Pharmacological interventions 
 
2.1 Anti-libidinal agents 
Pharmacological agents that seek to lower sexual drive are arguably the most established 
example of biological interventions used for crime prevention, though they are associated 
with significant controversy, and are still utilized relatively infrequently. The motivation 
for using such agents to prevent sexual re-offending is the thought that some sex crimes, 
especially those committed by paedophiles, are motivated in part by a misdirected sex 
drive. By diminishing sex drive, anti-libidinal agents may thus, in some classes of 
offender, diminish motivation to offend.  
 
The precursor to the use of such agents is surgical castration or orchidectomy, the 
surgical removal of both male testes. One of the earliest surgical procedures, surgical 
castration has been employed for a variety of reasons ranging from religious to musical to 
corrective. In the Middle Ages, it was applied as a retributive punishment for sex-related 
crimes such as rape or adultery.2 In the 20th Century, the procedure was re-introduced as a 
treatment and rehabilitative measure for sex offenders in a number of European countries, 
including Denmark, Germany, Norway, Finland, Estonia, Iceland, Latvia, and Sweden, 
                                                 
2 Nikolaus Heim, Carolyn J. Hursch, ‘Castration for Sex Offenders: Treatment or Punishment? A 
Review and Critique of Recent European Literature’, Archives of Sexual Behavior 8 (1979), pp. 
281–304. 
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where it was used under a range of legal provisions.3 Infamously, court-ordered castration 
for sex offenders was used widely in Nazi Germany, with more than 2800 orchidectomies 
carried out between 1934 and the abolition of the practice in 1944.4 Following World 
War II, the use of surgical castration decreased significantly worldwide, and it has been 
only rarely carried out, almost entirely on a voluntary basis, since the 1970’s.5 Currently, 
voluntary surgical castration for sex offenders is still offered in two European countries 
(the Czech Republic and Germany) and five U.S. states (California, Florida, Iowa, 
Louisiana and Texas).6  
 
The decline in the use of surgical castration was due in large part to ethical concerns. 
Surgical castration results in marked and irreversible psychological and physical changes 
including sterility, and it makes sexual activity difficult, if not impossible. 7  Many 
commentators have criticised the practice as a “cruel and unusual” punishment and an 
affront to human rights.8 The historical association of the practice with the totalitarian 
                                                 
3 Emma D. Stone, George L. Thurston, ‘Castration for Sexual Offenders. A Commentary on a 
Recent Case’, The Medico-Legal Journal 27 (1959), pp. 136–9. 
4  Michael Burleigh, Ethics and Extermination: Reflections on Nazi Genocide (Cambridge: 
Cambridge University Press, 1997). 
5 Kimberly A. Peters, ‘Chemical Castration: An Alternative to Incarceration’, Duquesne Law 
Review 31 (1992), pp. 307-328. 
6  Charles L. Scott, Trent Holmberg, ‘Castration of Sex Offenders: Prisoners’ Rights Versus 
Public Safety’, Journal of the American Academy of Psychiatry and Law 31 (2003), pp. 502–9; 
Laura S. Chism, ‘Case for Castration: A Shot towards Rehabilitation of Sexual Offenders’, Law 
and Psychology Review 37 (2013), pp. 193–209.  
7 Heim and Hursch, ‘Castration for Sex Offenders’; Peters, ‘Chemical Castration’. 
8 Council of Europe: Committee for the Prevention of Torture. Report to the German Government 
on the visit to Germany carried out by the European Committee for the Prevention of Torture and 
Inhuman or Degrading Treatment or Punishment (CPT), 2012; Council of Europe: Committee for 
the Prevention of Torture. Report to the Czech Government on the visit to the Czech Republic 
carried out by the European Committee for the Prevention of Torture and Inhuman or Degrading 
Treatment or Punishment (CPT), 2009. 
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regimes of Nazi Germany 9  and the USSR, 10  and in response to activities that were 
wrongly criminalised such as homosexuality,11 may also have contributed to its fall in 
popularity. There is, in addition, uncertainty regarding the actual efficacy of the practice 
in preventing re-offending, due to unavoidable methodological limitations and a sparse 
body of research, though there are suggestions that it was effective.12 
 
Anti-libidinal pharmacological agents aim to provide similar reductions in sexual drive 
and recidivism, but with the option of reversibility on discontinuation, and without the 
need for an invasive surgical procedure (the agents are normally administered by 
injection). They have typically been used to treat paraphilias, such as paedophilia, or to 
prevent sexual re-offending, with the two goals often being combined and, in some cases, 
conflated.  
 
Several pharmacological agents have been identified in the literature as potential anti-
libidinal agents. The two best established of these are cyproterone acetate (CPA), used 
widely in Europe, and medroxyprogesterone acetate (MPA), used widely in the United 
States. 13  Recently, gonadotrophin-releasing hormone (GnRH) agonists have been 
                                                 
9 Burleigh, Ethics and Extermination. 
10 Sidney Bloch, Paul Chodoff, Stephen A. Green, Psychiatric Ethics (Oxford: Oxford University 
Press, 1999). 
11 Geoffrey J. Giles, “The Most Unkindest Cut of All’: Castration, Homosexuality and Nazi 
Justice’, Journal of Contemporary History 27 (1992), pp. 41–61; Nikolaus Heim, ‘Sexual 
Behavior of Castrated Sex Offenders’, Archives of Sexual Behavior 10 (1981), pp. 11–9. 
12 Heim and Hursch, ‘Castration for Sex Offenders’; Friedrich Lösel and Martin Schmucker, ‘The 
Effectiveness of Treatment for Sexual Offenders: A Comprehensive Meta-Analysis’, Journal of 
Experimental Criminology 1 (2005), pp. 117–46; Linda E. Weinberger, Shoba Sreenivasan, 
Thomas Garrick, Hadley Osran, ‘The Impact of Surgical Castration on Sexual Recidivism Risk 
Among Sexually Violent Predatory Offenders’, Journal of the American Academy of Psychiatry 
and the Law 33 (2005), pp. 16-36. 
13 Harvey Gordon and Don Grubin, ‘Psychiatric Aspects of the Assessment and Treatment of Sex 
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employed for this purpose. 14  All of these agents are posited to act by lowering 
testosterone levels in the long-term, though GnRH agonists achieve this reduction 
through a less direct mechanism than CPA and MPA.15 When they are used with the goal 
of reducing testosterone activity to pre-pubescent levels they are frequently referred to as 
‘chemical castration’. They can produce significant and not uncommon medical side-
effects, including osteoporosis, weight gain, male breast enlargement, and hot flushes,16 
and CPA and MPA are also associated with deep venous blood clots and subsequent 
complications. Additionally, their use in the context of criminal justice has also provoked 
ethical debate regarding autonomy, consent, and coercion.17  
 
A fourth class of anti-libidinal agents, selective serotonin reuptake inhibitors (SSRIs), are 
psychotropic medications commonly used to treat depression and anxiety disorders, 
which have long been associated with a decrease in libido through poorly-understood 
                                                                                                                                                 
Offenders’, Advances in Psychiatric Treatment 10 (2004), pp. 73-80; Florence Thibaut, Flora De 
La Barra, Harvey Gordon, Paul Cosyns, John M. W. Bradford & the WFSBP Task Force on 
Sexual Disorders, ‘The World Federation of Societies of Biological Psychiatry (WFSBP) 
Guidelines for the Biological Treatment of Paraphilias’, The World Journal of Biological 
Psychiatry 11 (2010), pp. 604–55. 
14  Ariel Rösler, Eliezer Witztum, ‘Treatment of Men with Paraphilia with a Long-Acting 
Analogue of Gonadotropin-Releasing Hormone’, The New England Journal of Medicine 338 
(1998), pp. 416–22.  
15 Andreas Hill, Peer Briken, Christian Kraus, Kerstin Strohm, Wolfgang Berner, ‘Differential 
Pharmacological Treatment of Paraphilias and Sex Offenders’, International Journal of Offender 
Therapy and Comparative Criminology 47 (2003), pp. 407–21. 
16  Frederico D. Garcia and Florence Thibaut, ‘Current Concepts in the Pharmacotherapy of 
Paraphilias’, Drugs 71 (2011), pp. 771–90; Peer Briken and Martin P. Kafka, ‘Pharmacological 
Treatments for Paraphilic Patients and Sexual Offenders’, Current Opinion in Psychiatry 20 
(2007), pp. 609–13. 
17 John McMillan, ‘The Kindest Cut? Surgical Castration, Sex Offenders and Coercive Offers’, 
Journal of Medical Ethics 40 (2014), pp. 583-90; Thomas Douglas, Pieter Bonte, Farah 
Focquaert, Katrien Devolder, and Sigrid Sterckx, ‘Coercion, Incarceration, and Chemical 
Castration: An Argument from Autonomy’, Journal of Bioethical Inquiry 10 (2013), pp. 393–
405; Jesper Ryberg, ‘Is Coercive Treatment of Offenders Morally Acceptable? On the Deficiency 
of the Debate’, Criminal Law and Philosophy 9 (2015), pp. 619-631. 
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pathways.18 These medications are sometimes used for their anti-libidinal effects in sex 
offenders. 
 
The effectiveness of anti-libidinal agents in preventing sexual crimes is controversial. 
There are numerous methodological problems with the existing literature, stemming in 
part from the practical and ethical difficulties in conducting research on individuals with 
a history of sex offending. Aside from the ethical issues with the delivery of anti-libidinal 
agents themselves, there are significant research ethics concerns in allowing high-risk 
sexual offenders to remain untreated, as a randomised controlled trial might require, and 
in ensuring that research projects are fully voluntary and non-exploitative, given the 
vulnerable position of many offenders. Most researchers investigating anti-libidinal 
agents have also had to work within the practical constraints of the prison system, and 
many have been plagued by disruption from early release or transfers, and difficulties in 
adequately controlling for environmental conditions and demographics.  
 
A recent Cochrane systematic review of anti-libidinal agents for persons at risk for sexual 
offending highlights some of these difficulties with the evidence base. 19  Despite an 
exhaustive search of the literature, the authors were only able to identify seven 
randomised controlled trials that met their strict inclusion criteria. All of these studies 
were published prior to 1993, with samples sizes ranging from 9 to 37 participants; only 
                                                 
18 Deepak Prabhakar and Richard Balon, ‘How Do SSRIs Cause Sexual Dysfunction?’, Current 
Psychiatry 9 (2010), pp. 30–4. 
19 Omer Khan, Michael Ferriter, Nick Huband, Melanie J. Powney, Jane A. Dennis, and Conor 
Duggan, ‘Pharmacological Interventions for Those Who Have Sexually Offended or Are at Risk 
of Offending’, Cochrane Database of Systematic Reviews 2 (2015), DOI: 
10.1002/14651858.CD007989.pub2. 
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two formally measured rates of sexual recidivism; and none were conducted in a prison 
setting. Furthermore, considerable heterogeneity between study comparisons and 
outcome measures meant that quantitative meta-analysis was not considered possible by 
the authors. Given these significant limitations, the authors concluded that the existing 
high-quality literature was insufficient to draw firm conclusions on the effectiveness of 
anti-libidinal agents in preventing sexual recidivism. 
   
Although randomised controlled trials are considered the ‘gold-standard’ level of 
evidence, non-randomised trials can still provide useful data. Several non-systematic 
reviews including a broader range of study designs have also examined the literature 
surrounding anti-libidinal interventions. They have arrived at varying conclusions, 20 
depending on which trials were included and how their results were interpreted.  
 
Given these limitations, we have settled for commenting on three important papers on 
this topic: the Oregon Depo-Provera Trial, the largest single study on anti-libidinal 
interventions in a prison population;21 a meta-analysis by Lösel and Schmucker which 
constitutes the most inclusive quantitative review of interventions in sexual offenders to 
                                                 
20 Garcia and Thibaut, ‘Current Concepts in the Pharmacotherapy of Paraphilias’; Briken and 
Kafka, ‘Pharmacological Treatments for Paraphilic Patients and Sexual Offenders’; Marnie E. 
Rice and Grant T. Harris, ‘Is Androgen Deprivation Therapy Effective in the Treatment of Sex 
Offenders?’, Psychology, Public Policy, & Law 17 (2011), pp. 315-332; Frederico D. Garcia, 
Heloise G. Delavenne, Alessandra dFA Assumpção, and Florence Thibaut, ‘Pharmacologic 
Treatment of Sex Offenders with Paraphilic Disorder’, Current Psychiatry Reports 15 (2013), p. 
356; John M. W. Bradford, Paul Fedoroff, Sanjiv Gulati, ‘Can Sexual Offenders Be Treated?’, 
International Journal of Law and Psychiatry 36 (2013), pp. 235–40; Fabian M. Saleh and Fred S. 
Berlin, ‘Sex Hormones, Neurotransmitters, and Psychopharmacological Treatments in Men with 
Paraphilic Disorders’, Journal of Child Sexual Abuse 12 (2003), pp. 233–53. 
21  Barry M. Maletzky, Arthur Tolan, and Bentson McFarland, ‘The Oregon depo-Provera 
Program: A Five-Year Follow-Up’, Sex Abuse 18 (2006), pp. 303-16.  
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date; 22  and a review completed by the World Federation of Societies of Biological 
Psychiatry in developing their Guidelines for the Biological Treatment of Paraphilias, 
which constitutes the current expert opinion on the topic.23  
 
The Oregon Depo-Provera trial came about as a result of legislative changes in the US 
state of Oregon that required compulsory treatment with MPA on release in a selected 
population of sexual offenders, and was intended to evaluate the efficacy of the 
program.24 The study retrospectively followed the first cohort of men (n=275) inducted 
into the program between 2000 and 2004, separating the men into three groups: those 
prescribed MPA who indeed underwent treatment (n=79); those prescribed MPA but who 
for various reasons did not ultimately undergo treatment (n=55); and those judged to not 
require MPA (n=141). A number of methodological limitations were present. For 
example, detailed data concerning doses, timing and length of MPA administration were 
unavailable, as was information about serum testosterone levels and length of follow-up. 
In addition, decisions about which participants required anti-libidinal agents were based 
on an unvalidated risk scoring scale developed by the investigators, and no attempt was 
made to ensure equal baseline recidivism risk across the three groups. Nevertheless, the 
study arguably constitutes the strongest evidence on this topic available from a single 
piece of research, and the results were striking – only 5% of the group who actually 
received MPA committed new offences (p<0.0001), none of which were sexual in nature, 
                                                 
22 Lösel and Schmucker, ‘The Effectiveness of Treatment for Sexual Offenders’. 
23  Thibaut et al., ‘The World Federation of Societies of Biological Psychiatry (WFSBP) 
Guidelines’. 
24 Barry M. Maletzky, Gary Field, ‘The Biological Treatment of Dangerous Sexual Offenders: A 
Review and Preliminary Report of the Oregon Pilot depo-Provera Program’, Aggression and 
Violent Behavior 8 (2003), pp. 391–412. 
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compared with a 26-30% re-offense rate in the other two groups, with just over half of 
these offences being sexual in nature. None of the MPA treated group returned to prison, 
compared to 15-20% of the other two groups (p<0.0001 for recommended and did not 
receive, p<0.002 for not recommended). As has been noted elsewhere, 25  that the 
recidivism rates for the two non-treated groups correlates well with reported sexual 
offender recidivism rates from other studies, providing some weak support for the 
reliability of the study’s results.26  
 
Lösel and Schmucker’s meta-analysis is, to date, the most comprehensive quantitative 
review undertaken of the efficacy of surgical and chemical castration in preventing sexual 
re-offending.27 The authors examined 69 studies from multiple countries that met their 
inclusion criteria, with 80 separate comparisons totalling over 22,000 individuals. Of 
these, 6 studies assessed the efficacy of anti-libidinal agents, and 8 studies examined 
surgical castration. Both interventions, but especially surgical castration, were found to 
have large, statistically significant effects in reducing recidivism, more so than any other 
intervention examined. The authors do, however, strike a cautionary tone, noting that 
many of the studies do not reach ‘gold-standard’ levels of design quality, and are still 
subject to methodological limitations even after passing inclusion criteria. Subjects often 
receive these therapies in conjunction with other cognitive-behavioural interventions, 
introducing potential confounders, and are furthermore (particularly with surgical 
                                                 
25 Briken and Kafka, ‘Pharmacological Treatments for Paraphilic Patients and Sexual Offenders’. 
26  R. Karl Hanson and Kelly E. Morton-Bourgon, ‘The Characteristics of Persistent Sexual 
Offenders: A Meta-Analysis of Recidivism Studies’, Journal of Consulting and Clinical 
Psychology 73 (2005), pp. 1154–63.  
27Lösel and Schmucker, ‘The Effectiveness of Treatment for Sexual Offenders’. 
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castration) often voluntary and thus administered only to a highly selected population. 
Despite these issues, the authors nevertheless conclude that there is an overall significant 
and positive effect with these interventions, and that they should be considered for use, in 
combination with other modes of treatment, in sexual offenders.  
 
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the 
Biological Treatment of Paraphilias were the result of a specially appointed Task Force 
on Sexual Disorders aiming to provide expert clinical guidelines for the treatment of 
paraphilias and sexual disorders.28 The Task Force undertook an extensive review of the 
literature, evaluated the efficacy of a range of anti-libidinal agents in the treatment of 
sexual disorders, and produced a graded treatment algorithm for a range of paraphilias. 
There was, however, no quantitative analysis of treatment effects; in contrast to the Lösel 
and Schmucker study, the WSFBP review aimed to arrive at an agreed expert opinion, 
rather than undertaking a detailed meta-analysis. The existing evidence was not found to 
support the use of SSRIs due to a lack of sufficient research, with a possible exception 
being patients that exhibit obsessive-compulsive elements in their paraphilia. MPA and 
CPA were both thought to be effective, though conclusions were limited by the 
moderately poor quality of the existing evidence due to methodological limitations. More 
importantly, they had multiple significant side effects that were of substantial concern 
and would limit their use. The newer class of GnRH antagonists (including triptorelin, 
leuprolin, and goserelin) also suffered from the limited quality of existing research, but 
appeared to be more potent than CPA and MPA, with fewer side effects reported. The 
                                                 
28  Thibaut et al., ‘The World Federation of Societies of Biological Psychiatry (WFSBP) 
Guidelines’. 
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Task Force concluded that, overall, there was some evidence that anti-libidinal agents can 
have an anti-recidivist effect and that they should be utilised in conjunction with other 
modes of treatment, and regular medical follow-up.  
 
Overall, this body of evidence could be taken to suggest that the use of hormonal anti-
libidinal agents is likely to be effective in reducing sexual recidivism in selected groups 
of sexual offenders, but has medically significant side-effects. However, any firm 
conclusion is precluded by the issues with the existing research literature noted above.  
 
2.2 Pharmacological treatments for substance abuse and addiction 
Substance abuse and addiction (SA/A) are linked rather directly to criminal behaviour – 
in most jurisdictions around the world, the possession, sale, and use of so-called illicit 
drugs, not including alcohol, is a criminal offence.29 In the United States, a significant 
fraction of the dramatic increase in the prison population since the 1970’s can be 
attributed to a rising number of inmates arrested on drug-related charges as part of the 
‘war on drugs’.30  
 
There is also evidence for a relationship between SA/A and other criminal offenses, 
particularly violent crimes, with strong associations present in many surveys of offenders 
and inmates. Among the general prison population in the US, nearly 70% of State 
                                                 
29 Marcus Roberts, Axel Klein, and Mike Trace, ‘Towards A Review of Global Policies on Illegal 
Drugs’, The Beckley Foundation Drug Policy Programme (2004). Available at 
http://reformdrugpolicy.com/wp-content/uploads/2011/09/report_1globalpolicy.pdf.  
30  Philip J. Cook and Jens Ludwig, ‘Economical Crime Control’, The National Bureau of 
Economic Research No. 16513 (2010). Available at http://www.nber.org/papers/w16513; David 
Bewley-Taylor, ‘Getting High on the Policy Agenda: Europe, the US and the Future of the Global 
Drug Prohibition Regime’, Journal of Transatlantic Studies 4 (2006), pp. 27-53. 
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prisoners reported regular use of illicit drugs, 56% in the month prior to, and 33% at the 
time of offence.31 In comparison, 7.9% of the general American population over the age 
of 12 reported being current users of illicit drugs (use during the immediate month prior) 
in the same year.32 A large systematic review found estimates of between 10-60% for the 
prevalence of drug and alcohol SA/A in prison populations.33 Australian data indicates 
that as many as two in three people detained by police for offenses tested positive for 
illicit drugs (not including alcohol), and complementary survey data have suggested that 
up to 45% of offenses are self-attributed to either alcohol or illicit drug use.34  
 
Of course, these associations between use of illicit drugs and criminal offending mask a 
more complex and multifactorial picture. None of the commonly-used substances have 
direct biological effects that are sufficient to, in and of themselves, produce violent 
behaviour or offending. Rather, they constitute risk factors interacting within a 
miscellaneous milieu of social, cultural, institutional, and (underlying) biological 
factors.35 One schematic framework suggests three basic means via which SA/A can 
promote violence: systemic violence (turf wars and conflicts resulting from procurement 
and distribution); economic-compulsive violence (economically-oriented crimes 
committed to support the acquisition of addictive substances); and 
                                                 
31 Christopher J. Mumola and Jennifer C. Karberg, ‘Drug Use and Dependence, State and Federal 
Prisoners, 2004’, US Department of Justice, Office of Justice Programs, Bureau of Justice 
Statistics (2006). Available at https://www.bjs.gov/content/pub/pdf/dudsfp04.pdf.  
32 ‘Results from the 2004 National Survey on Drug Use and Health: National Findings’, NSDUH 
Series H-28. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2005. 
Available at http://medicalmarijuana.procon.org/sourcefiles/2k4results.pdf.  
33 Seena Fazel, Parveen Bains, and Helen Doll, ‘Substance Abuse and Dependence in Prisoners: 
A Systematic Review’, Addiction 101 (2006), pp. 181–91. 
34 Adam Tomison, ‘How Much Crime Is Drug or Alcohol Related? Self-Reported Attributions of 
Police Detainees’, Trends & Issues in Crime and Criminal Justice 439 (2009), pp. 421-40.  
35 Tomison, ‘How Much Crime Is Drug or Alcohol Related?’. 
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psychopharmacological violence (aggressive behaviour attributable in part to biological 
side-effects of substance use).36 Surveys suggest that systemic violence is most prevalent, 
with economic-compulsive and psychopharmacological violence constituting small but 
still significant categories. 37  Of course, most violence associated with SA/A likely 
involves a mixture of these factors, rather than one in isolation. 
 
The latter two, economic-compulsive and psychopharmacological violence are most 
relevant to this discussion, being most directly related to direct biological effects of 
SA/A. Presumably, the addictive properties of many illicit (and licit) drugs are an 
important driver of economic-compulsive violence, and thus treatment of SA/A would be 
expected to prevent or reduce this sort of offending. Psychopharmacological violence 
provoked by the short- and long-term cognitive, psychological, and behavioural changes 
induced by abuse or withdrawal from certain drugs – including irritability, anxiety, 
psychomotor agitation, physical aggression and even psychosis – is also likely amenable 
to treatment of SA/A.  
 
Traditionally, behavioural and psychosocial interventions such as cognitive behavioural 
therapy (CBT) and twelve-step programs form the backbone of community SA/A 
treatment programs.38 There are, however, a number of pharmacological therapies have 
                                                 
36 Bruce D. Johnson, Paul J. Goldstein, Edward Preble, James Schmeidler, Douglas S. Lipton, 
Barry Spunt, and Thomas Miller, Taking Care of Business: The Economics of Crime by Heroin 
Abusers (Lexington, MA: Lexington Books, 1985).  
37 Paul J. Goldstein, Henry H. Brownstein, Patrick J. Ryan, and Patricia A. Bellucci, ‘Crack and 
Homicide in New York City, 1988: A Conceptually Based Event Analysis’, Contemporary Drug 
Problems 16 (1989), pp. 651-88. 
38 Benjamin R. Nordstrom and Frances R. Levin, ‘Treatment of Cannabis Use Disorders: A 
Review of the Literature’, American Journal on Addictions 16 (2007), pp. 331-42; Molly Magill 
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also recently been found to be effective in treating SA/A in the outpatient setting, 
especially in combination with the above interventions. These include topiramate, an anti-
epileptic, and buprenorphine, a weak opioid agonist, but the strongest evidence is for the 
use of opioid antagonists and methadone maintenance therapy (MMT). High-quality 
systematic reviews find that opioid antagonists significantly reduce the risk of heavy 
drinking, as well as the overall amount and frequency of alcohol consumption in 
alcoholics, 39  and that MMT significantly reduces the use of heroin and improves 
treatment program retention in narcotic addicts.40  
 
Evidence on the effectiveness of these interventions in the criminal justice system 
specifically is much sparser, and suffers from methodological limitations. The most 
widely-studied and promising intervention in this particular setting is MMT,41 though the 
literature is still limited and the actual availability of these interventions in prisons is 
poor.42 A wide array of observational and higher-quality randomised controlled trials 
agree that MMT is effective in reducing drug relapse rates and improving treatment 
program retention and uptake.43  
                                                                                                                                                 
and Lara A. Ray, ‘Cognitive-Behavioral Treatment with Adult Alcohol and Illicit Drug Users: A 
Meta-Analysis of Randomized Controlled Trials’, Journal of Studies on Alcohol and Drugs 70 
(2009), pp. 516–27. 
39 S. Rosner, A. Hackl-Herrwerth, S. Leucht, S. Vecchi, M. Srisurapanont, and M. Soyka, ‘Opioid 
Antagonists for Alcohol Dependence’, Cochrane Database of Systematic Reviews 12 (2010), 
DOI: 10.1002/14651858.CD001867.pub2. 
40 Rosner et al., ‘Opioid Antagonists for Alcohol Dependence’. 
41 Redonna K. Chandler, Bennett W. Fletcher, and Nora D. Volkow, ‘Treating Drug Abuse and 
Addiction in the Criminal Justice System: Improving Public Health and Safety’, JAMA 301 
(2009), pp. 183–90; Stephen J. Bahr, Amber L. Masters, and Bryan M. Taylor, ‘What Works in 
Substance Abuse Treatment Programs for Offenders?’, The Prison Journal 92 (2012), pp. 155–
74. 
42 Steven Belenko, Matthew Hiller, and Leah Hamilton, ‘Treating Substance Use Disorders in the 
Criminal Justice System’, Current Psychiatry Reports 15 (2013), pp. 1-11. 
43  Bahr, Masters, and Taylor, ‘What Works In Substance Abuse Treatment Programs for 
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Whether there is a similarly substantial effect in reducing criminal activity, recidivism, 
and re-incarceration is still uncertain, with conflicting conclusions from high-quality 
reviews of the evidence. A recent systematic review of opioid maintenance therapy in 
prison settings,44 and a meta-analysis of a range of incarceration-based drug treatment 
programs 45  concluded that the evidence from trials with MMT painted a mixed but 
                                                                                                                                                 
Offenders?’; Martin Killias, Marcelo Aebi, Miriam Pina, Nicole Egli, and Pernille S. Christensen, 
‘Effects of Drug Substitution Programs on Offending Among Drug-Addicts’, Campbell 
Systematic Reviews 3 (2009); Kate A. Dolan, James Shearer, Bethany White, Jialun Zhou, John 
Kaldor, and Alex D. Wodak, ‘Four-Year Follow-Up of Imprisoned Male Heroin Users and 
Methadone Treatment: Mortality, Re-Incarceration and Hepatitis C Infection’ Addiction 100 
(2005), pp. 820-8; Sara L. Johnson, Jennifer T. C. van de Ven, and Brian Grant, ‘Institutional 
Methadone Treatment: Impact on Release Outcome and Institutional Behaviour’, Research 
Report 119 (2001); Wayne Hall, Jeff Ward, and Richard Mattick, ‘Methadone Maintenance 
Treatment in Prisons: The New South Wales Experience’ Drug and Alcohol Review 12 (1993), 
pp. 193–203; Vincent P. Dole, J. Waymond Robinson, John Orraca, Edward Towns, Paul Searcy, 
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England Journal of Medicine 280 (1969), pp. 1372–5; Dagmar Hedrich, Paula Alves, Michael 
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Stallwitz and Heino Stöver, ‘The Impact of Substitution Treatment in Prisons – A Literature 
Review’, International Journal of Drug Policy 18 (2007), pp. 464–74; Lars M. Gunne and Leif 
Grönbladh, ‘The Swedish Methadone Maintenance Program: A Controlled Study’, Drug and 
Alcohol Dependence 7 (1981), pp. 249–56; Johann A. Koehler, David K. Humphreys, Thomas D. 
Akoensi, Olga Sánchez de Ribera, and Friedrich Lösel, ‘A Systematic Review and Meta-Analysis 
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Law 20 (2014), pp. 584–602; Timothy W. Kinlock, Michael S. Gordon, Robert P. Schwartz, 
Terrence T. Fitzgerald, and Kevin E. O’Grady, ‘A Randomized Clinical Trial of Methadone 
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Treatment 37 (2009), pp. 277–85; Michael S. Gordon, Timothy W. Kinlock, Robert P. Schwartz, 
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Wilson M, ‘A Randomized Clinical Trial of Methadone Maintenance for Prisoners: Results at 
One-Month Post-Release’, Drug and Alcohol Dependence 91 (2007), pp. 220–7; Timothy W. 
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Maintenance for Male Prisoners 3-Month Postrelease Outcomes’, Criminal Justice and Behavior 
35 (2008), pp. 34–47. 
44 Hedrich et al., ‘The Effectiveness of Opioid Maintenance Treatment in Prison Settings’. 
45 Ojmarrh Mitchell, David B. Wilson, and Doris L. MacKenzie, ‘Does Incarceration-Based Drug 
Treatment Reduce Recidivism? A Meta-Analytic Synthesis of the Research’, Journal of 
Experimental Criminology 3 (2007), pp. 353–75. 
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overall neutral picture, with varying results reported. In contrast, a recent systematic 
review and meta-analysis of drug treatment programs for offenders in Europe46 and a 
systematic review of a variety of pharmacological substitution-based programmes 47 
suggest that such interventions are indeed effective in facilitating a significant reduction 
in criminal behaviour. In the light of such conflicts, it is suggested that further high-
quality research with larger sample populations are required to confirm the benefits of 
MMT.  
 
2.3 Pharmaceutical treatments for ADHD 
ADHD is a neurodevelopmental disorder that typically begins in childhood, and is 
characterized by high-for-age levels of inattention and/or hyperactivity and impulsivity. It 
is commonly associated with poor academic performance in school, and difficulties with 
social interaction, and can persist into adulthood.48  
 
ADHD is significantly associated with criminal offending. In corrective institutions 
worldwide, numerous studies have consistently found a disproportionately high 
prevalence of ADHD. Although some of these studies suffered from significant 
methodological weaknesses, the results indicated that between 24 and 67% of adolescent 
prisoners met the criteria for childhood ADHD, and between 23-45% of adult prisoners 
met the criteria for adult ADHD.49  For comparison, a large pooled meta-analysis of 
                                                 
46 Koehler et al., ‘A Systematic Review and Meta-Analysis on the Effects of European Drug 
Treatment Programmes on Reoffending’.  
47 Killias et al., ‘Effects of Drug Substitution Programs on Offending Among Drug-Addicts’. 
48 Benjamin J. Sadock and Virginia A. Sadock, Kaplan & Sadock’s Synopsis of Psychiatry: 
Behavioral Sciences/Clinical Psychiatry (Philadephia, PA: Lippincott Williams & Wilkins, 2007).  
49 Toshihiko Matsumoto, Akiko Yamaguchi, Takeshi Asami, Atsushi Kamijo, Eizo Iseki, Yoshio 
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global studies on the prevalence of ADHD suggested the worldwide pooled rate was 
5.29%.50   
 
It is more difficult to establish the exact causal link between ADHD and criminality, as 
there is significant co-morbidity with multiple psychiatric conditions that are themselves 
risk factors for criminal behaviour, particularly substance abuse and addiction, 
oppositional defiant disorder (ODD) and conduct disorder (CD).51 Multiple longitudinal 
and retrospective cohort studies, however, have supported a significant increase in risk 
for criminal offending with ADHD, even after controlling for OD and CDD co-
morbidity.52 One particularly prominent theory regarding the association between ADHD 
                                                                                                                                                 
Hirayasu, and Kiyoshi Wada, ‘Drug Preferences in Illicit Drug Abusers with a Childhood 
Tendency of Attention Deficit/Hyperactivity Disorder: A Study Using the Wender Utah Rating 
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(ADHD) in Personality Disordered Offenders and the Association with Disruptive Behavioural 
Problems’, The Journal of Forensic Psychiatry & Psychology 14 (2003), pp. 491–505; Gisli H. 
Gudjonsson, Jon F. Sigurdsson, Susan Young, Anna K. Newton, Marius Peersen, ‘Attention 
Deficit Hyperactivity Disorder (ADHD). How Do ADHD Symptoms Relate to Personality 
Among Prisoners?’, Personality and Individual Differences 47 (2009), pp. 64–8; M. Rosler, W. 
Retz, P. Retz-Junginger, G. Hengesch, M. Schneider, T. Supprian, P. Schwitzgebel, K. Pinhard, 
N. Dovi-Akue, P. Wender, and J. Thome, ‘Prevalence of Attention Deficit-/Hyperactivity 
Disorder (ADHD) and Comorbid Disorders in Young Male Prison Inmates’, European Archives 
of Psychiatry and Clinical Neuroscience 254 (2004), pp. 365–71. 
50 Guilherme Polanczyk, Maurício S. de Lima, Bernardo L. Horta, Joseph Biederman, and Luis A. 
Rohde, ‘The Worldwide Prevalence of ADHD: A Systematic Review and Metaregression 
Analysis’, The American Journal of Psychiatry 164 (2007), pp. 942–8. 
51 Catrina M. Schilling, Anthony Walsh, Ilhong Yun, ‘ADHD and Criminality: A Primer on the 
Genetic, Neurobiological, Evolutionary, and Treatment Literature for Criminologists’, Journal of 
Criminal Justice 39 (2011), pp. 3-11. 
52 Leslie M. Babinski, Carolyn S. Hartsough, Nadine M. Lambert, ‘Childhood Conduct Problems, 
Hyperactivity-impulsivity, and Inattention as Predictors of Adult Criminal Activity’, The Journal 
of Child Psychology and Psychiatry 40 (1999), pp. 347-55; Terrie E. Moffitt, ‘Juvenile 
Delinquency and Attention Deficit Disorder: Boys’ Developmental Trajectories from Age 3 to 
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R. Blevins, Leah Daigle, James D. Unnever, ‘The Relationship of Attention Deficit Hyperactivity 
Disorder to Crime and Delinquency: a Meta-Analysis’, International Journal of Police Science & 
Management 4 (2002), pp. 344–60; James H. Satterfield, Katherine J. Faller, Francis M. Crinella, 
Anne M. Schell, James M. Swanson, Louis D. Homer, ‘A 30-Year Prospective Follow-Up Study 
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and criminality in the criminology literature is that it results from the poor impulse 
control often seen in ADHD.53  
 
Fortunately, ADHD is also one of the most successfully treatable psychiatric conditions.54  
Stimulant medications, such as methylphenidate, have been found effective in treating the 
disorder in numerous large and well-designed randomized controlled trials.55 A review of 
the literature by the American Academy of Paediatrics strongly supported the 
effectiveness of stimulant medications in treating symptoms of ADHD.56  
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54 Russell A. Barkley, Kevin R. Murphy, Mariellen Fischer, ADHD in Adults: What the Science 
Says (New York: Guilford Press, 2010). 
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Howard M. Schachter, Ba’ Pham, Jim King, Stephanie Langford, David Moher, ‘How 
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Deficit/Hyperactivity Disorder: Overview of the Evidence’, Pediatrics 115 (2005), pp. e749-57. 
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As ADHD is strongly associated with criminal offending, the effective treatment of this 
condition might be expected to reduce the risk of criminal behaviour. A recent large 
Swedish retrospective cohort study has reported findings that support this conclusion57 – 
in 25,565 adult subjects diagnosed with ADHD, the untreated control group had an 
overall 12% increased risk of criminal conviction during the follow-up period compared 
to the treated group. Despite the open-label design and reliance on registry data, the 
results were statistically significant and robust under multiple sensitivity analyses. 
 
2.4 Modulating serotonin levels to attenuate aggression 
Another promising area of recent interest has been the role that different neurotransmitter 
systems play in mediating social behaviour. This has included work examining the effects 
of oxytocin on trust,58 adrenaline on racial bias,59 and serotonin on various aspects of 
social behaviour. In what follows we briefly exemplify this research by setting out some 
of the relevant findings regarding serotonin.  
 
                                                 
57 Paul Lichtenstein, Linda Halldner, Johan Zetterqvist, Arvid Sjolander, EvaSerlachius E, Seena 
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Increases Trust in Humans’, Nature 435 (2005), pp. 673-6; Paul J. Zak, Robert Kurzban, William 
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59  Sylvia Terbeck, Guy Kahane, Sarah McTavish, Julian Savulescu, Philip J. Cowen, Miles 
Hewstone, ‘Propranolol Reduces Implicit Negative Racial Bias’, Psychopharmacology 222 
(2012), pp. 419-24. 
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There is an enormous body of animal research literature concerning the relationship 
between the neurotransmitter serotonin and social behaviour, implicating it in behaviours 
ranging from parental attachment and mating, to co-operation and aggression. In 
particular, lower central serotonin levels were associated with increased proactive 60 
aggression in mice, and a number of genes involved in the synthesis and metabolism of 
serotonin have been associated with aggressive behaviours.61 
 
In humans, the serotonergic neurotransmitter system has been implicated in aggression 
and antisocial behaviour, though its role has not been fully elucidated.62 Levels of a 
serotonin metabolite in cerebrospinal fluid, for example, are significantly lower in 
antisocial subjects compared to healthy controls. 63  Variations in the gene coding for 
MAOA, an enzyme in the brain that breaks down serotonin, have also been strongly 
associated with aggressive behaviour in certain social contexts.64 A mutation in the gene 
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coding for the 5-HT2B serotonin receptor has also been identified in a series of violent 
Finnish offenders, and subsequent experiments in mice suggest it is associated with 
increased levels of impulsivity and aggressive behaviours.65  
 
The serotonin deficiency hypothesis – that levels of brain serotonin are inversely 
correlated with aggressive behaviour – is currently the most popular explanation of the 
relationship. Some support for this hypothesis can be derived from a series of studies 
which assessed the effects of acute tryptophan depletion on aggressive behaviours. 
Tryptophan is an amino acid that is a metabolic precursor to serotonin, and reduction in 
circulating blood plasma levels is a validated experimental method to indirectly reduce 
brain serotonin levels.66 The studies found that depletion of tryptophan, and thus of neural 
serotonin, significantly increased behavioural and self-reported measures of aggression, 
with greater effects in those with aggressive tendencies. 67 Conversely, a randomised, 
                                                                                                                                                 
Activity’, Biological Psychiatry 59 (2006), pp. 121–7.  
65 Laura Bevilacqua, Stéphane Doly, Jaakko Kaprio, Qiaoping Yuan, Roope Tikkanen, Tiina 
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Chase, et al., ‘Converging Evidence for Central 5-HT Effects in Acute Tryptophan Depletion’, 
Molecular Psychiatry 17 (2012), pp. 121–3. 
67 Donald M. Dougherty, James M. Bjork, Dawn M. Marsh, F. Gerard Moeller, ‘Influence of 
Trait Hostility on Tryptophan Depletion-Induced Laboratory Aggression’, Psychiatry Research 
88 (1999), pp. 227–32; James M. Bjork, ‘Behavioral Effects of Plasma Tryptophan Depletion in 
Aggressive and Nonaggressive Men’, Texas Medical Center Dissertations (via ProQuest) (1999). 
Available at 
http://search.proquest.com/docview/304576742?accountid=14553%5Cnhttp://openurl.library.uiuc
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Depletion and Aggressive Responding in Healthy Males’, Psychopharmacology 126 (1996), pp. 
97–103; James M. Bjork, Donald M. Dougherty, F. Gerard Moeller, Don R. Cherek, Alan C. 
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controlled double-blind study found that augmentation of central serotonin levels by 
administration of SSRIs 68  attenuated aggressive responses, particularly in participants 
with a history or aggression.69   
 
A recent comprehensive meta-analysis of over 6,500 total participants in 175 studies and 
across four different experimental methods tested the validity of this serotonin deficiency 
hypothesis, and found a small, but reliable inverse relationship between serotonin levels 
and aggression. 70  The investigators noted, however, that there was significant 
heterogeneity in results of studies within similar experimental methods.  
 
More specifically, a number of recent reviews have also suggested that serotonin 
deficiency may be more closely related to impulsive (as opposed to instrumental) 
aggression. 71  Impulsive aggression is usually characterised as a reactive, emotional 
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Time Course and a Food-Restricted Control’, Psychopharmacology 142 (1999), pp. 24–30; A. J. 
Cleare, A. J. Bond, ‘The Effect of Tryptophan Depletion and Enhancement on Subjective and 
Behavioural Aggression in Normal Male Subjects’, Psychopharmacology 118 (1995), pp. 72–81. 
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69 Mitchell E. Berman, Michael S. McCloskey, Jennifer R. Fanning, Julie A. Schumacher, Emil F. 
Coccaro, ‘Serotonin Augmentation Reduces Response to Attack in Aggressive Individuals’, 
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response to a provocative stimulus, and is associated with antisocial personality disorder. 
Instrumental aggression, on the other hand, is described as pre-meditated, less 
emotionally motivated, and carried out with the intent of achieving a particular goal or 
reward, and is associated with psychopathy.  
 
If serotonin deficiency increases aggression, it might be expected also to contribute to the 
occurrence of certain kinds of violent and sexual crime. Further, we might speculate that 
drugs which increase serotonin levels will tend to diminish the likelihood that an 
individual will commit such crimes. These thoughts remain highly speculative, however; 
we are not aware of any high quality studies directly investigating the effect of serotonin 
levels or SSRIs on criminality.  
 
There is also a further mechanism via which serotonin neurobiology might influence 
criminality. Recent work by Crockett et al. suggests that depletion of tryptophan tends to 
increase the degree to which individuals will sacrifice their own interests in order to 
punish those who have treated them unfairly; that is, it seems to strengthen the disposition 
to engage in costly retaliation.72  
 
How might this be useful in developing future interventions to reduce criminality? It has 
been suggested that retaliatory dispositions are, in at least some instances, implicated in 
violent or criminal behaviour. The psychologist Stephen Pinker argues that one 
contributor to violent behaviour is a combination of retaliatory dispositions and positive 
                                                 
72 Molly J. Crockett, Annemieke Apergis-Schoute, Benedikt Herrmann, Matthew D. Lieberman, 
Ulrich Müller, Trevor W. Robbins, Luke Clark, ‘Serotonin Modulates Striatal Responses to 
Fairness and Retaliation in Humans’, The Journal of Neuroscience 33 (2013), pp. 3505–13. 
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self-evaluation. 73  That is, certain criminal behaviour (e.g. blood feuds, retaliatory 
violence, and code-of-honour retribution) is the result of a desire to mete out ‘justice’, as 
well as an unfortunate tendency to think that we are, more often than not, on the 
aggrieved side. It is not implausible that dampening this drive for retaliation might be a 
means of reducing criminal or violent behaviour.74  
 
3. Nutritional interventions 
Adequate nutrition, particularly at critical stages in early life, is important for normal 
neurodevelopment, and poor nutrition increases the risk of developmental and psychiatric 
disorders later in life. Severe malnutrition in the first and second trimesters, 75  for 
example, has been associated with a significantly greater rate of antisocial personality 
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disorder in later life. This is a psychiatric condition characterized by impulsivity, 
aggression, disregard for others, and criminal behaviour.76  
 
Postnatally, early childhood malnutrition is also associated with an increased risk of 
externalising behaviours – aggression, hyperactivity, attention problems and delinquency 
– in later childhood and teenage years. Such behaviours are themselves a significant risk 
factor for juvenile delinquency, and criminal offending and violence in adulthood.77 A 
large prospective longitudinal study of 1795 Mauritian children 78  found that 
malnourishment at age 3 was associated with significantly higher overall rating for 
externalising behaviours at ages 8, 11 and 17 years. This relationship was independent of 
gender, ethnicity, and psychosocial adversity (captured by adverse parental, family, or 
housing factors), but controlling for cognitive ability (IQ) abolished the main effects of 
malnutrition in the statistical analysis. This suggests that poor neurodevelopment may be 
the causal link between malnourishment and subsequent externalising behaviour. A 
smaller prospective cohort study of 213 Jamaican children79 assessed the effect of early 
childhood stunting on psychosocial functioning and behaviour in later childhood and 
adolescence. Stunting (growth retardation) is associated with under-nutrition and 
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infectious diseases, and is particularly common in areas of low socioeconomic status. 
Children who experienced early stunting had increased prevalence of antisocial and 
oppositional behaviours in late adolescence80 in comparison to their non-stunted peers. A 
report on a cohort of Barbadian children81 who experienced a limited episode of protein-
energy malnutrition also suggested that they were more likely, in comparison to healthy 
controls, to display aggressive behaviour towards their peers, oppositional-defiant 
behaviours towards adults, and attention-deficit issues in later childhood (ages 5-11). 
These behaviours persisted through to late adolescence (ages 11-17) but were somewhat 
attenuated.82 
 
More reassuringly, however, there is some evidence to suggest that early malnutrition is 
at least partially amenable to mitigation through early intervention programs including 
nutritional supplementation.83 Individuals who have not experienced malnutrition may 
also benefit from nutritional supplementation, with a number of studies showing 
behavioural improvements in ‘healthy’ cohorts. There have been, to date, three well-
designed, randomised controlled trials of nutritional supplementation in young adult 
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pp. 1627–35. 
 28 
prisoners, all of which have suggested that they produce a robust and significant 
improvement in behaviour.  
 
The earliest, by Schoenthaler et al, was a double-blinded randomised controlled trial in 62 
inmates of a maximum-security psychiatric facility aged between 13 and 17. 84  The 
subjects were given supplements containing high-dose minerals and vitamins over an 
experimental period of 13 weeks. Nutritional status assessment and dietary advice was 
also given to all subjects, regardless of whether they were in the active or placebo group. 
Voluntary blood samples before, and after, the experiment were also collected for about 
half the study group. Compared to the 13-week initial baseline period, violent infractions 
fell 80% in the active group (56% in the placebo group); non-violent infractions fell 83% 
(49% with placebo); and total infractions fell 83% (55% with placebo). The treatment 
effect for supplementation was 4.236 (p=0.044) for violent infractions; 7.646 (p=0.008) 
for non-violent rule infractions; and 8.517 (p=0.005) for total rule infractions. There were 
also some indications that this decrease in rule-breaking was mediated by underlying 
changes in nutrient levels, with improvements in behaviour correlating with correction of 
pre-experimental nutrient deficiencies.  
 
A second double-blinded, randomised controlled trial of 231 young inmates in the United 
Kingdom also strongly suggested that nutritional supplementation (including omega fatty 
                                                 
84 Stephen J. Schoenthaler, Stephen Amos, Walter Doraz, Mary-Ann Kelly, George Muedeking, 
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acids) was effective in reducing antisocial behaviour in the prison system.85 An intention-
to-treat analysis found that inmates on supplementation committed, overall, 26.3% fewer 
disciplinary offenses compared to those on placebo (p<0.03). A more specific analysis 
excluding drop-outs and subjects who showed poor compliance or were started on 
psychotropic medication found a more pronounced decrease in disciplinary incidents of 
35.1% (compared to 6.7% for placebo), which was particularly pronounced for serious 
(including violent) offenses.   
 
Zaalberg et al. attempted to reproduce these results, conducting a similar study in a Dutch 
cohort of young prisoners, enlisting 326 subjects.86 105 (32%) did not complete the trial, 
mainly for practical reasons including early release or transfer, and no significant 
differences in a variety of characteristics were found between completers and drop-outs. 
The results of the trial replicated a significant reduction in rule-breaking incidents with 
supplementation, as well as non-significant improvements in scores of aggression and 
psychological wellbeing. One note of caution, however, is that there were indications that 
participants managed, in one way or another, to identify whether they were treatment or 
placebo group, with a significant increase in correct guesses of group assignments 
throughout the trial. Thus, it is possible that differences between the groups were due to 
differences in expectations rather than the treatment itself.  
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Overall, there is a substantial body of evidence suggesting that adequate nutrition in the 
pre-natal, post-natal, and childhood periods is essential to normal behavioural 
development, and that, conversely, malnutrition increases the risk of antisocial and 
delinquent behaviour later in life. These behavioural sequelae of early childhood 
malnutrition appear to be at least partially reversible by appropriate programs of 
enrichment and nutrition. This would seem to indicate a simple and promising means of 
intervening to reduce future risk of criminality in at-risk populations and young 
delinquents. Even more intriguing is the aforementioned small but high-quality body of 
evidence suggesting that nutritional supplementation can rapidly and substantially reduce 
antisocial and rule-breaking behaviour in prisoners, perhaps through the correction of 
underlying micronutrient deficiencies. Whatever the mechanism, and pending further 
investigation and replication in the post-release setting, this may present a cheap, 
effective, and readily available means of reducing recidivism and criminal behaviour. 
 
4. Brain stimulation techniques 
One further mode of intervention that may, speculatively, be capable of modulating 
dispositions to violently offend is the family of interventions that can be loosely referred 
to as electromagnetic brain stimulation (EBS): deep brain stimulation (DBS), transcranial 
magnetic stimulation (TMS) and transcranial direct-current stimulation (tDCS). Each of 
these involves the application of magnetic fields or electrical currents, via different 
methods, to specific areas of the brain, with the aim of modulating brain activity. DBS 
involves the invasive neurosurgical placement of metal electrodes within the brain to 
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transmit electrical impulses.87 TMS and tDCS, on the other hand, non-invasively induce 
changes in brain activity through the use of superficial magnets 88  and electrodes 89 
respectively. These two modes have a shallow depth of effective penetration relative to 
DBS and are thus only able to affect relatively superficial brain regions. 90  Recent 
developments in TMS technology, though, suggest it may be possible to extend this 
range.91 Both DBS and TMS already have FDA-approved medical indications: the former 
for essential tremor and Parkinson’s disease, 92  dystonia 93  and obsessive-compulsive 
disorder;94 and the latter for migraine95 and treatment-resistant depression.96  
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More recently, the use of EBS interventions to therapeutically alter cognitive, 
psychological and behavioural outcomes has been explored, although this possibility 
remains largely speculative. This has not, however, dampened enthusiasm, and the 
resulting popularity and proliferation of mass-market “DIY brain stimulation kits” have 
necessitated serious considerations about the appropriate way to regulate such devices.97  
 
How might EBS interventions be useful in preventing or reducing criminal conduct? The 
basic thought is that it could be used to up- or down-regulate brain activity in the brain 
regions responsible for modulating (anti-)social behaviour.   
 
It is important to recognise that there are a variety of interventions already in use, aside 
from EBS, that alter both brain structure and functional activity and human behaviour– 
including psychotherapies 98  such as cognitive behavioural therapy 99  and mindfulness 
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meditation. 100  EBS interventions aim to produce similar outcomes, but improve 
specificity and reliability through targeting brain activity as a means to behavioural 
outcomes. To illustrate this, consider neurofeedback, a novel technique that is arguably 
midway between traditional therapies and EBS. Neurofeedback utilises real-time 
functional magnetic resonance imaging (rtfMRI) and biofeedback methods to train 
subjects to consciously modulate levels of brain activity in specific regions of interest.101 
In other words, neurofeedback arguably constitutes a form of non-electrical brain 
stimulation; and already studies suggest that it can produce corresponding behavioural 
changes associated with stimulation of these brain areas, including emotional 
processing,102 linguistic ability,103 and even reductions in chronic pain.104  
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Currently, there are three main crime-relevant psychological dispositions or processes 
that the literature suggests may be modifiable by EBS: moral cognition, aggression, and 
impulsivity. 
 
Many criminal activities, particularly violent crimes such as rape, murder, and bodily 
assault, are almost universally recognised as immoral. Deficits or abnormalities in moral 
cognition may, then, increase the likelihood of criminal offending, with psychopathy and 
antisocial personality disorder (APD) as extreme examples of such cases. De Ridder et al. 
detail evidence from functional imaging studies for abnormal brain functioning in two 
conditions associated with criminal offending – APD and paedophilia.105 They argue that 
it would theoretically be possible to remedy these abnormalities through the use of 
electrical brain stimulation, with the use of TMS for initial therapeutic trials, and the later 
implantation of DBS electrodes to maintain a permanent therapeutic effect. There are also 
some early indications that tDCS may be able to modulate moral decision-making and 
behaviour,106 but these studies are preliminary, utilise small sample sizes, and require 
replication. There are, to our knowledge, as yet no studies assessing directly for 
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therapeutic effects of any EBS modality on the conditions mentioned above, or indeed 
measures of criminal offending.  
 
Aggression and impulsivity are two dispositions that are often thought to increase the risk 
of antisocial and criminal behaviour,107 and have been linked with altered brain activity in 
the prefrontal cortex and amygdala.108 Modifying these through EBS may be a possible 
means to prevent criminal behaviour. There are some indications in the sparse literature 
that this may indeed be possible – Dambacher et al., for example, found that receiving 
tDCS to the right dorsolateral prefrontal cortex (DLPFC) significantly decreased 
measures of proactive aggression in men.109 Even more interestingly, a trial by Riva et al. 
found that tDCS potentially mitigates the increase in aggression associated with social 
exclusion. 110  Participants experiencing simulated social exclusion who also received 
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stimulation of the right ventrolateral prefrontal cortex (VLPFC) were significantly less 
aggressive than those who did not, and were indistinguishable from those who experience 
simulated social inclusion. Aggressive behaviour resulting from social exclusion, the 
authors note, may place a role in certain criminal behaviours, including domestic violence 
and school shootings. In addition to these, a number of small experimental studies 
similarly suggest that modulation of regions in the pre-frontal cortex through tDCS and 
TMS has an effect on propensities for risk-taking behaviour111 and higher-order cognitive 
inhibitory control.112  
 
As will be evident, currently much of the support for the use of EBS to reduce or prevent 
criminal behaviour is highly speculative, consisting mainly of small-scale, as-yet 
unreproduced cognitive science experiments.  Two highly critical quantitative reviews of 
tDCS have recently been published (by the same author) arguing that the existing 
evidence, in aggregate, indicates that tDCS is almost completely ineffective;113 these 
                                                                                                                                                 
Stimulation’, Social Cognitive and Affective Neuroscience 10 (2015), pp. 352-6. 
111 Shirley Fecteau, Daria Knoch, Felipe Fregni, Natasha Sultani, Paulo Boggio, Alvaro Pascual-
Leone, ‘Diminishing Risk-Taking Behavior by Modulating Activity in the Prefrontal Cortex: A 
Direct Current Stimulation Study’, The Journal of Neuroscience 27 (2007), pp. 12500–5; Shirley 
Fecteau, Alvaro Pascual-Leone, David H. Zald, Paola Liguori, Hugo Theoret, Paulo S. Boggio, 
Felipe Fregni, ‘Activation of Prefrontal Cortex by Transcranial Direct Current Stimulation 
Reduces Appetite for Risk during Ambiguous Decision Making’, The Journal of Neuroscience 27 
(2007), pp. 6212–8. 
112  Liron Jacobson, Daniel C. Javitt, Michal Lavidor, ‘Activation of Inhibition: Diminishing 
Impulsive Behavior by Direct Current Stimulation over the Inferior Frontal Gyrus’, Journal of 
Cognitive Neuroscience 23 (2011), pp. 3380–7; Tzu-Yu Hsu, Lin-Yuan Tseng, Jia-Xin Yu, Wen-
Jiu Kuo, Daisy L. Hung, Ovid J. L. Tzeng, et al., ‘Modulating Inhibitory Control with Direct 
Current Stimulation of the Superior Medial Frontal Cortex’, NeuroImage 56 (2011), pp. 2249–57; 
Chi-Hung Juan, Neil G. Muggleton, ‘Brain Stimulation and Inhibitory Control’, Brain 
Stimulation 5 (2012), pp. 63–9. 
113 Jared Cooney Horvath, Jason D. Forte, Olivia Carter, ‘Quantitative Review Finds No Evidence 
of Cognitive Effects in Healthy Populations from Single-Session Transcranial Direct Current 
Stimulation (tDCS)’, Brain Stimulation 8 (2015), pp. 535–50; Jared Cooney Horvath, Jason D. 
Forte, Olivia Carter, ‘Evidence That Transcranial Direct Current Stimulation (tDCS) Generates 
 37 
articles have themselves, however, come under scrutiny for their statistical analyses and 
methodology.114 As things currently stand, much research and further therapeutic trials 
will need to be conducted before EBS is even able to be considered as a viable alternative 
or adjunct in the criminal justice system.  
 
5. Final thoughts 
This chapter has reviewed six biological kinds of intervention that one might reasonably 
expect, in the future, to be deployed, or at least advocated, for the purposes of preventing 
crime. Four of these have already been used or trialled in this role. The fifth and sixth—
modulation of the serotonergic bases of aggression and retaliatory dispositions, and EBS 
interventions to specifically alter moral cognition, aggression, or impulsivity – are 
speculative but somewhat promising possibilities for the future.115 
 
Crime is inherently social both in the sense that it affects other people, and in the sense 
that social context has an influence on the effectiveness of any crime prevention 
technique. It is therefore important to note that many of the findings we have reviewed in 
this chapter are based on empirical studies conducted with individuals acting alone in the 
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closed environment of the laboratory. It has, however, been shown that biological factors 
in principle can affect people differently when they are studied as isolated individuals 
from when they act in a social group. This has, for example, been empirically shown for 
stress116 and for alcohol,117 and it has been argued that this is likely to be also the case for 
other biological factors, including pharmacological substances.118 Future research needs 
not only to confirm that the techniques we discussed can be effective in individuals in the 
laboratory, but also in non-laboratory settings. 
 
To conclude our discussion, we would like to note some potentially significant 
differences between the six kinds of intervention that we have discussed.   
 
One difference relates to the (notoriously problematic) distinction between the natural 
and the artificial. With one possible exception, all of the interventions we discussed are 
‘artificial’ in the sense that they involve the deployment of products produced through 
complex, human-designed processes. The possible exception is nutrition, which arguably 
need not involve the use of such products, and might be deemed by some to be a ‘natural’ 
intervention.  
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A second difference pertains to the distinction between therapy and enhancement. 
Therapies are often understood as interventions that are intended to correct a disease, 
disorder or disability, whereas enhancements aim to augment human capacities from an 
already healthy level. 119  (There is, of course, much debate about how to draw the 
boundaries of ‘disease, disorder and disability’, and thus about the correct application of 
the therapy-enhancement distinction.) Two of the interventions that we discussed are, as 
we understood them, necessarily therapeutic, for they are defined by the disorders that 
they treat—namely, substance abuse or addiction and ADHD. However, it is possible that 
the same pharmaceuticals could be used with similar effects in individuals who possess 
some tendencies towards substance abuse, addiction, poor attention, or hyperactivity, 
though they would not qualify for any disorder. The other kinds of intervention that we 
survey were not characterised such that they are necessarily therapeutic, though in some 
cases they might be. For instance, nutritional interventions might be used to correct 
malnutrition and associated behavioural abnormalities (therapeutic) or to improve on 
already-healthy nutritional states and behavioural tendencies (enhancement), and anti-
libidinal agents are typically used partly for the purpose of treating paraphilias.  
 
Of course, it might turn out, in relation to some of these interventions that they are 
effective in preventing criminal offending only in cases where they constitute therapies. 
For instance, the best evidence for the preventive effectiveness of anti-libidinal 
interventions relates to their use in individuals who would qualify for a diagnosis of 
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paraphilia. It is much less clear whether anti-libidinal interventions could prevent sexual 
offending in individuals who suffer from no disorder.  
 
It should also be noted that on some ways of drawing the therapy-enhancement 
distinction, all interventions used to prevent crime would constitute therapies. Some 
would view all interventions that aim to correct or prevent abnormalities as therapeutic, 
and criminal conduct is arguably always abnormal, even if it is not always accompanied 
by a disease, disorder or disability. Still, there are plausible and standard ways of drawing 
the therapy-enhancement distinction such that some of the interventions we have 
discussed are not therapeutic.   
 
There are, then, at least two oft-made distinctions that might be drawn between the kinds 
of intervention we have discussed: the artificial-natural distinction, and the therapy-
enhancement distinction. In identifying these differences, we do not mean to suggest that 
they are of moral significance; whether they are has been the subject of much recent 
discussion in the literature on the ethics of biomedical enhancement. We leave this as a 
topic for further debate.  
